OBJECTIVE： To study the effects of goserelin on vascular growth factor and immune function of rats with prostatic hyperplasia. METHODS： Rats were selected to establish prostatic hyperplasia model and randomly divided into model group， goserelin low-dose， medium-dose and high-dose groups （0.4， 0.8， 1.2 mg/kg）； normal rats were selected as normal control group， with 10 rats in each group. Normal control group and model group were given normal saline intragastrically， and goserelin groups were given relevant dose of drugs intragastrically， once a day， for consecutive 25 days. The prostate volume， wet weight， prostatic index of rats were detected as well as positive cell area of VEGF， TGF-β1， FGF， CD4 and CD8 in prostate tissue. RESULTS： Compared with normal control group， prostate volume， wet weight， prostatic index， positive cell area of VEGF， TGF-β1， FGF， CD4 and CD8 were all increased in model group （P＜0.05）. Compared with model group， the above indexes of goserelin groups were all improved （P＜0.05）， especially those in medium-dose and high-dose groups were better than in low-dose group （P＜0.05）； there was no statistical significance between medium-dose group and high-dose group （P＞0.05）. CONCLUSIONS： Goserelin can relieve prostatic hyperplasia of rats， reduce the expression of VEGF in prostate tissue and regulate immune function.